



Irma Grossi, PhD, MBA

Sr. Director, Preclinical Pharmaceutical Sciences

Dr. Irma (Gina) Grossi has more than 12 years of experience in preclinical drug development for investigational new drug (IND) application filings. Dr. Grossi is highly involved in the technical efforts of RTI Health Solutions' Preclinical Pharmaceutical Sciences, as evidenced by her current role in developing a commercially focused and integrated drug development group to fully support preclinical programs.

Areas of Expertise

- Change management
- In vivo drug development and risk assessment
- Preclinical toxicology
- Regulatory submissions
- Program development and management

Dr. Grossi has also served as Principal Investigator (PI) on multiyear contracts for anti-AIDS therapies and antineoplastic drugs for the National Cancer Institute (NCI), where she was the focal point of all program communications and was responsible for the technical and fiscal components of each study. As PI for the National Institute of Neurological Disorders and Stroke research contract, she was responsible for both managing and completing all scientific and programmatic aspects of the project in standardizing rodent models and developing novel therapeutics in the treatment of Parkinson's disease.

Experience

Dr. Grossi received her PhD in cancer biology in 1991 from Wayne State University School of Medicine and continued her training as a postdoctoral fellow in tumor immunology at Bristol Myers-Squibb Research Pharmaceuticals. She gained experience as a scientific group leader, research analyst, study director, and director of research. Dr. Grossi joined Battelle Memorial Institute in 1999, where she served as the product line manager of Commercial Toxicology and the PI for an NCI-sponsored project to develop new therapeutics for the treatment of cancer and HIV. Upon her promotion to Senior Program Director, Toxicology, Dr. Grossi played a key role in product management to determine and facilitate the drug development process in support of U.S. Food and Drug Administration INDs, new drug applications, and U.S. Environmental Protection Agency and European registrations.

Since joining RTI Health Solutions in 2005, Dr. Grossi has been instrumental in planning and implementing preclinical development programs for new lead

Contact

RTI Health Solutions
Research Triangle Park, NC, USA
+1.800.262.3011

Ann Arbor, MI, USA
+1.734.213.5372

Barcelona, Spain
+34.93.241.7766

Manchester, UK
+44(0)161.232.3400

Waltham, MA, USA
+1.781.434.1700

rtihealthsolutions@rti.org
www.rtihs.org

(continued)

Irma Grossi, PhD, MBA

Sr. Director, Preclinical Pharmaceutical Sciences



candidates in accordance with GLP, monitoring technical and financial performance, as well as establishing and initiating corrective action where indicated. Her extensive experience leading multidisciplinary teams for a range of contracts for government-sponsored programs, biotechnology firms, and multinational corporations gives her the flexibility to perform a variety of cross-discipline roles for RTI-HS's clients.

Dr. Grossi's research in cancer biology, toxicology, and pharmacokinetics has appeared in many publications, including 19 peer-reviewed journal articles, several book chapters, and 40 abstracts. She also speaks fluent Italian and conversational Spanish, has served as an adjunct associate professor in toxicology for Ohio State University's School of Public Health, and has represented RTI since 2006 on the board of directors for the North Carolina Association for Biomedical Research.

Dr. Grossi's strong background in drug development for pulmonary applications has helped to further expand RTI-HS's preclinical and non-clinical research services.

**For information about
preclinical pharmaceutical
sciences, please contact**

Paul Borron, MSc, PhD
Scientist, Business Development
Preclinical Pharmaceutical Sciences

Phone: +1.919.541.6208
E-mail: pborron@rti.org

RTI Health Solutions
3040 Cornwallis Road
PO Box 12194
Research Triangle Park,
NC 27709-2194 USA

